Establishment and characterization of the permanent human cell line C3842 derived from a secondary chondrosarcoma in Ollier's disease.
The permanent human cell line C3842 was established from a secondary chondrosarcoma in a typical case of Ollier's disease. In the present study, we analyzed the morphological, cytogenetic and molecular biological characteristics of the cultured cells in comparison with the original tumor and investigated the invasion properties of the tumor model using functional imaging of proteolysis, matrigel assay and chick chorioallantoic membrane assay. C3842 cells exhibit the typical features of malignant cartilage tumor cells in vitro, including the expression of collagen types II, IX, XI and aggrecan. The proteolytic ability of C3842 cells is attributed to the expression of several proteases, such as cathepsin B, urokinase plasminogen activator and matrix-metalloproteinase-2, which enable the cells to degrade collagen type I and to permeate matrigel matrix. In accordance with the biological features in vivo, C3842 cells are not able to invade through the epithelium of the chick chorioallantoic membrane. In conclusion, the cell line C3842 provides the first model of a secondary chondrosarcoma in Ollier's disease in vitro, which is characterized by distinct features of such malignant cartilage tumors.
Kalinski
Thomas
T
Department of Pathology, Otto-von-Guericke-University, Leipziger Strasse 44, 39120 Magdeburg, Germany. kalinski@medizin.uni-magdeburg.de
Krueger
Sabine
S
Pelz
Antje-Friederike
AF
Wieacker
Peter
P
Hartig
Roland
R
Röpke
Martin
M
Schneider-Stock
Regine
R
Dombrowski
Frank
F
Roessner
Albert
A
D000328:Adult; D000818:Animals; D001859:Bone Neoplasms / Q000150:complications* / Q000473:pathology / Q000648:ultrastructure; D045744:Cell Line, Tumor / Q000502:physiology* / Q000648:ultrastructure; D002813:Chondrosarcoma / Q000150:complications* / Q000473:pathology / Q000648:ultrastructure; D049033:Chorioallantoic Membrane; D002869:Chromosome Aberrations; D004687:Enchondromatosis / Q000150:complications*; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D009361:Neoplasm Invasiveness; D018807:Polymorphism, Single-Stranded Conformational; D020133:Reverse Transcriptase Polymerase Chain Reaction
Cancer Genet Cytogenet. 1998 Sep;105(2):128-33
9723029
Cancer. 2002 Apr 15;94(8):2273-81
12001127
Cancer Gene Ther. 2001 Jul;8(7):522-8
11498774
Clin Cancer Res. 1996 Apr;2(4):613-8
9816210
Anticancer Res. 1997 Sep-Oct;17(5A):3201-10
9413149
Genes Chromosomes Cancer. 2002 Feb;33(2):188-200
11793445
Am J Hum Genet. 1991 Jan;48(1):137-44
1670750
Virchows Arch A Pathol Anat Histopathol. 1990;417(4):291-7
2122578
APMIS. 2001 Apr;109(4):305-15
11469503
Invasion Metastasis. 1992;12(5-6):241-52
1298737
Clin Exp Metastasis. 1992 May;10(3):145-55
1582084
Cancer Res. 1989 Jul 15;49(14):3996-4002
2736538
Cancer. 2000 Sep 1;89(5):995-1003
10964329
Cancer. 1987 Apr 1;59(7):1376-85
3815310
J Clin Oncol. 2003 May 1;21(9):1688-97
12721243
Hum Pathol. 2000 Oct;31(10):1299-303
11070122
Am J Pathol. 2000 Nov;157(5):1587-95
11073818
Mol Imaging. 2003 Jul;2(3):159-75
14649059
Matrix Biol. 1996 Jul;15(2):91-8
8837010
FEBS Lett. 1989 Dec 4;258(2):195-8
2599085
Cancer. 1997 Jan 1;79(1):53-8
8988726
Virchows Arch. 1998 Jun;432(6):529-34
9672194
Cancer. 1974 Nov;34(5):1642-52
4426028
J Bone Joint Surg Am. 1999 Mar;81(3):326-38
10199270
J Orthop Res. 1998 Sep;16(5):521-30
9820274
Clin Orthop Relat Res. 1974 May;(100):378-86
4365130
J Cancer Res Clin Oncol. 1999 Oct;125(10):541-8
10473866
Int J Cancer. 1998 Sep 11;77(6):854-9
9714054
Anal Biochem. 1987 Apr;162(1):156-9
2440339
Virchows Arch. 2003 Dec;443(6):725-33
14513378
J Cell Biochem. 1996 Oct;63(1):37-50
8891902
Lab Invest. 2003 Jun;83(6):877-87
12808123
Am J Pathol. 1997 Jun;150(6):2133-41
9176404
J Urol. 2001 Oct;166(4):1502-7
11547121
Cancer Genet Cytogenet. 1993 Sep;69(2):79-90
8402563